|
|
|
|
|
Last Trade
|
Last Trade:
$188.30
|
Change:
1.20 (0.64%)
|
Trade Time:
Sep 17
|
Market Cap:
$48.85B
|
|
|
|
|
|
|
Description of Business
|
|
We are a global biotechnology company that invests in scientific innovation to
create transformative medicines for people with serious diseases with a focus on
specialty markets.
Cystic Fibrosis
Our goal is to develop treatment regimens that will provide benefits to all
people with cystic fibrosis, or CF, and will enhance the benefits currently
provided to people taking our medicines. Our marketed medicines are
TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and
ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI
(lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Our triple combination regimen,
TRIKAFTA/KAFTRIO, was approved in 2019 in the United States, or U.S., and in
2020 in the European Union, or E.U. Collectively, our four medicines are
approved to treat the majority of the approximately 83,000 people with CF in
North America, Europe and Australia.
|
|
|
|